Molecular and Cellular Biochemistry

, Volume 399, Issue 1–2, pp 1–5 | Cite as

Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma

  • Hongliang Liu
  • Wei Liu
  • Bin Zhu
  • Qiang Xu
  • Xiaowei Ni
  • Ji Yu
Article
First Online:
Received:
Accepted:

Abstract

The LHX genes play a substantial role in an amount of adorning processes. Potential roles of LHXs have been accepted and approved in an assortment of neoplastic tissues as bump suppressors or promoters depending on bump cachet and types. The aim of this abstraction was to investigate the action role of LHXs in the animal High-grade Oligodendroglioma (HG-OT). The gene announcement changes of LHXs in HG-OT tissues compared with non-cancerous colorectal tissues were detected using application real-time quantitative about-face transcriptase-polymerase alternation acknowledgment (QRT-PCR) assay and immunohistochemistry. And we articulate the gene LHX3 that was decidedly up-regulated in HG-OT by QRT-PCR assay and immunohistochemistry. Furthermore, it was obvious that LHX3 responds to blight corpuscle admeasurement in vitro and LHX3 announcement activated with animated β-catenin levels in HG-OT and β-catenin action was appropriate for LHX3’s oncogenic effects.  Mechanistically, LHX3 facilitates TCF4 to bind to β-catenin and facilitates LHX3/TCF4/β-catenin circuitous and trans-active it’s after ambition gene. LHX3 mutations that agitate the LHX3-β-catenin alternation partially anticipate its action in bump cells. All in all, LHX3 is a frequently activated bump apostle that actuates Wnt/β-catenin signaling in blight beef of HG-OT.

Keywords

LHX3 Oncogene HG-OT β-Catenin 
This is a preview of subscription content, log in to check access.

Notes

Conflicts of interest

None

References

  1. 1.
    Sheng HZ et al (1996) Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Science 272:1004–1007PubMedCrossRefGoogle Scholar
  2. 2.
    Sharma K et al (1998) LIM homeodomain factors Lhx3 and Lhx4 assign subtype identities for motor neurons. Cell 95:817–828PubMedCrossRefGoogle Scholar
  3. 3.
    Netchine I et al (2000) Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet 25:182–186PubMedCrossRefGoogle Scholar
  4. 4.
    Ino Y et al (2001) Molecular subtypes of anaplastic oligodendroglioma implications for patient management at diagnosis. Clin Cancer Res 7:839–845PubMedGoogle Scholar
  5. 5.
    Cairncross JG, Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Annal Neurol 23:360–364PubMedCrossRefGoogle Scholar
  6. 6.
    Fritz AG (2000) International classification of diseases for oncology: ICD-O. World Health Organization, GenevaGoogle Scholar
  7. 7.
    Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393PubMedCrossRefGoogle Scholar
  8. 8.
    Perencevich M, Stoffel EM (2011) A multidisciplinary approach to the diagnosis and management of multiple colorectal polyps. Gastroenterol Hepatol 7:420Google Scholar
  9. 9.
    Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6:479–507PubMedCrossRefGoogle Scholar
  10. 10.
    Gerstung M, Eriksson N, Lin J, Vogelstein B, Beerenwinkel N (2011) The temporal order of genetic and pathway alterations in tumorigenesis. PLoS ONE 6:e27136PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138:2073–2087 e2073PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Pevny LH, Lovell-Badge R (1997) < i > Sox </i > genes find their feet. Curr Opin Genet Dev 7:338–344PubMedCrossRefGoogle Scholar
  13. 13.
    Kormish JD, Sinner D, Zorn AM (2010) Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease. Dev Dyn 239:56–68PubMedCentralPubMedGoogle Scholar
  14. 14.
    Kiefer JC (2007) Back to basics: sox genes. Dev Dyn 236:2356–2366PubMedCrossRefGoogle Scholar
  15. 15.
    Bafico A, Liu G, Goldin L, Harris V, Aaronson SA (2004) An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6:497–506PubMedCrossRefGoogle Scholar
  16. 16.
    Liu F, Millar SE (2010) Wnt/beta-catenin signaling in oral tissue development and disease. J Dent Res 89:318–330PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Franklin MC et al (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317–328PubMedCrossRefGoogle Scholar
  18. 18.
    Agus DB et al (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127–137PubMedCrossRefGoogle Scholar
  19. 19.
    Muthuswamy SK, Gilman M, Brugge JS (1999) Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19:6845–6857PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Hongliang Liu
    • 1
  • Wei Liu
    • 1
  • Bin Zhu
    • 1
  • Qiang Xu
    • 1
  • Xiaowei Ni
    • 1
  • Ji Yu
    • 2
  1. 1.Department of Neurosurgery, Huashan Hospital Baoshan BranchFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Neurosurgery, Huashan HospitalFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations